Clene's Stock Gain As Its Nanotherapeutic Improves Energy Production, Brain Utilization In Patients With Parkinson's, Multiple Sclerosis

Clene Inc CLNN has shared positive top-line results from the Phase 2 REPAIR trials investigating the improvement of brain energetic metabolism in Parkinson's disease (PD) and multiple sclerosis (MS).
The objective of the REPAIR program was to demonstrate the effects of Clene's nanotherapeutic, CNM-Au8, on brain energy metabolites in two studies of patients with Parkinson's disease (REPAIR-PD) and multiple sclerosis (REPAIR-MS).
Patients were imaged before and after 12 or more weeks of daily oral dosing with CNM-Au8.
The results for the primary endpoint, the mean change in the brain NAD+/NADH ratio (the ratio of the oxidized to a reduced form of nicotinamide adenine dinucleotide), demonstrated a statistically significant increase by an average of 0.589 units (10.4%).
The individual results for these sister studies demonstrated consistent statistical trends toward improvement in the NAD+/NADH ratio.
CNM-Au8 treatment was well tolerated, with all treatment-emergent adverse events reported as predominantly mild and unrelated to the study drug.
There were no serious adverse events or treatment discontinuations related to adverse events in either study.
The clinical endpoint of MDS-UPDRS in REPAIR-PD showed no worsening of clinical status across the study population.
Price Action: CLNN shares are up 6.59% at $9.38 during the premarket session on the last check Thursday.